Announcement
James T. Joins Mavengity as a Medical Writer
With James now writing full time for our Healthcare & Medical desk, Mavengity has formally expanded into dedicated medical authorship.
Read the Article
Posted in the last 24 hours
Fresh from the desks
Gene Editing
As Gene Therapy for Deafness Advances, the Real Question Is How It's Offered
A wave of startups in the U.S., France, and China is racing toward gene therapies for the most common genetic causes of deafness, following the FDA's April approval of the first such treatment. The science is moving fast, but it's arriving into a genuine tension between families who want it and a Deaf community with legitimate reasons for wariness.
Medicare Policy
How Medicare's Weight-Loss Drug Program Could Become Its Own Argument Against Coverage
Medicare's Bridge program offers GLP-1 weight-loss drugs for $50 a month, but a physician warns the paperwork behind that price could suppress its own usage. Low uptake caused by burdensome administration would look identical to low demand, and that manufactured verdict could be used to justify never making coverage permanent.
Credit
Why Credit-Card Delinquencies Look Worse Than They Are
The New York Fed's consumer-report delinquency measure looks alarming, but a chunk of it is stale debt banks charged off years ago that still lingers on credit reports. The rate isn't wrong, it's counting a stock of old distress as if it were a live flow of new distress.
Tax Policy
A Trump Account Is Really Two Programs, Depending on Your Income
New Treasury and IRS rules let employers put up to $2,500 tax-free into a child's Trump Account. That tax shield is worth three times as much to a top earner as a modest one, and nothing to families who owe no tax, while the account's flat $1,000 seed treats every child the same.
Credit
Cars Got Too Expensive, So Lenders Are Stretching the Loans Instead
Auto-loan originations hit a record $211 billion in Q2 2026 even as subprime delinquencies rival the Great Recession. Lenders aren't being reckless so much as absorbing an affordability problem, stretching loan terms to make an unaffordable car's monthly payment look manageable.
Medicaid Policy
Why People Who Still Qualify Keep Losing Their Medicaid
New Medicaid work requirements and twice-yearly eligibility checks take effect in 2027. The central danger isn't that ineligible people will be removed, it's that eligible people will lose coverage simply because they can't get through the paperwork, and research shows that's cheap to prevent.
Clinical Trials
The Trouble With "Targeted" Radiation: It Still Hits the Kidneys on the Way to the Tumor
Radiopharmaceuticals were pitched as precision radiation that spares healthy tissue. As more of them reach clinical trials, developers are finding the isotopes damage kidneys, livers, and bone marrow on the way to the tumor, a structural tradeoff rather than a fixable glitch.
Science Policy
Why China Is Reining In the Very Clinical-Trial System the U.S. Wants to Copy
American researchers want to copy the fast, lightly reviewed investigator-initiated trials that helped China pull ahead in biotech. China is now tightening that same system after safety and transparency problems, including a patient death. The timing is the whole story.
Pharma Supply Chain
When a Life-Sustaining Drug Depends on a Single Factory
Sanofi is running short of two enzyme-replacement drugs that Pompe disease patients depend on to stay stable, tracing to a quality bottleneck at a single Irish plant. The shortage exposes a structural fragility built into how rare-disease medicines are made, not a failing unique to one company.
B2B Research
Most Popular Research Articles
AI Platforms
AI Foundation Models
In 2024 Forrester ranked the large language models themselves. Two years later the category split in two, and the split says something real about how enterprises actually buy AI.
AI Consulting
AI Consulting Services
The firms winning the largest AI advisory engagements in 2026 are not the ones with the strongest strategic reputation. They are the ones that can carry a plan past the slide deck and into production.
AI Decisioning
AI Decisioning Platforms
The vendors leading this category are not the names most associated with artificial intelligence. They are credit scoring firms and rules engine companies, because what is being sold is accountability, not intelligence.
AIOps
AIOps Platforms
Compare the 2022 and 2025 vendor lists and the interesting story is not who scored well, it is who stopped existing. AIOps is not dying, it is being absorbed by the observability platforms that already own the telemetry.
Process Orchestration
Adaptive Process Orchestration Software
Forrester and Gartner named the same emerging market within months of each other and gave it two different names. Comparing the definitions shows what each firm thinks actually matters.
Event Management
All-In-One Event Management Platforms
Twenty-two percent of large enterprises run six or more separate event technology platforms. This category is the consolidation answer, and the inclusion criteria are the whole story.
Customer Data Platforms
B2B Customer Data Platforms
Forrester's 2023 evaluation assessed standalone B2B CDP providers. By 2025 the word standalone was gone, and two of the vendors named Leaders were Adobe and Oracle.
Cloud Cost Management
Cloud Cost Management And Optimization Solutions
Multicloud cost visibility is now commodity functionality. Differentiation has moved to optimization depth, and almost every independent vendor in this category has already been acquired by an infrastructure company.
Digital Asset Management
Digital Asset Management Systems
For twenty years a DAM was a library for the creative team. It is now the place an enterprise keeps the only content its AI tooling is allowed to treat as authoritative.
Announcements
News from Mavengity
Browse by topic
Where would you like to start?
Every article on Mavengity is written by a dedicated topic desk and checked against current market practice.
Insurance
Home, auto, life, and health coverage, explained clearly and checked against the fine print.
Browse InsuranceMortgage
Rates, refinancing, and first-time buyer strategy, without the jargon lenders assume you already know.
Browse MortgagePersonal Finance
Budgeting, saving, and everyday money habits that compound. No get-rich-quick promises.
Browse Personal FinanceLegal
Contracts, consumer rights, and disputes, explained so you know where you stand.
Browse LegalHealthcare & Medical
Health coverage and medical billing, broken down so surprise bills are less likely to surprise you.
Browse HealthcareResearch
Gartner and Forrester categories for B2B, translated into plain-English analysis for buyers, not analyst-subscription holders.
Browse Research
Why Mavengity
Editorial standards you can check
Independently researched
We start from public rate filings, regulator guidance, and lender disclosures, not marketing copy.
Plain-English explanations
If a term needs a footnote, we explain it in the sentence instead of hiding it in the fine print.
Straight, not slanted
We flag trade-offs and blind spots, not just the upside, so you get the full picture before you decide.
Written for readers, not lenders
Mavengity is reader-supported and editorially independent from the products we cover.